Clinical Trials Logo

Macular Degeneration clinical trials

View clinical trials related to Macular Degeneration.

Filter by:

NCT ID: NCT01950741 Active, not recruiting - Clinical trials for Polypoidal Choroidal Vasculopathy

Effect of Intravitreal VEGF-Trap Eye on Polypoidal Choroidal Vasculopathy

VAULT
Start date: September 2013
Phase: Phase 4
Study type: Interventional

Effects of VEGF Trap-Eye (aflibercept) in treatment-naive polypoidal choroidal vasculopathy (PCV) will be evaluated.

NCT ID: NCT01943396 Active, not recruiting - Clinical trials for Age Related Macular Degeneration

Treatment of AMD With Rheohemapheresis /RHF/

TARHF
Start date: September 2013
Phase: Phase 4
Study type: Interventional

In this research rheohemapheresis will be used for the treatment of patients with high-risk dry form of age-related macular degeneration. Correction of rheologic parameters and activation of retinal functional reserves after the therapy will positively influence functional condition of retina. The newest special electrophysiologic methods will be used to determine retinal changes in time. The investigators will also evaluate some important immunologic factors and complement changes as well as define indication criteria more precisely.

NCT ID: NCT01918878 Active, not recruiting - Clinical trials for Neovascular Age-related Macular Degeneration

Aflibercept (EYLEA)as Secondary or Third Line Treatment for Neovascular Age-related Macular Degeneration.

Start date: October 2013
Phase: Phase 4
Study type: Interventional

This is a prospective, multicenter, single arm study. The study group will be compose of NVAMD patients who had partial or complete failure responding to initial bevacizumab or ranibizumab treatment of 3-6 monthly intravitreal injections. The patients in the study groups will receive 5 intravitreal injections of aflibercept 2mg/0.05ml at specific visits. Aflibercept will be provided for total period of 24 weeks.

NCT ID: NCT01782352 Active, not recruiting - Clinical trials for Age-related Macular Degeneration

Age-related Macular Degeneration (AMD) in the Vitamin D and Omega-3 Trial (VITAL)

Start date: July 2010
Phase: N/A
Study type: Interventional

The VITamin D and OmegA-3 Trial (VITAL; NCT 01169259) is a randomized clinical trial in 25,875 U.S. men and women investigating whether taking daily dietary supplements of vitamin D3 (2000 IU) or omega-3 fatty acids (Omacor fish oil, 1 gram) reduces the risk of developing cancer, heart disease, and stroke in people who do not have a prior history of these illnesses. This ancillary study is being conducted among participants in VITAL and will examine whether vitamin D or omega-3 fatty acids, compared to placebo, reduce the incidence and/or progression of age-related macular degeneration (AMD).

NCT ID: NCT01777984 Active, not recruiting - Clinical trials for Age-related Macular Degeneration

Impact of Visceral Fat on the Pathogenesis of Age-related Macular Degeneration

Start date: December 2009
Phase: N/A
Study type: Observational

The purpose of this study is to determine the relationship among the body fat distribution, especially the visceral fat, in patients with age-related macular degeneration in comparison to patients with a normal fundus.

NCT ID: NCT01736592 Active, not recruiting - Stargardt's Disease Clinical Trials

Phase I/II Follow-up Study of SAR422459 in Patients With Stargardt's Macular Degeneration

Start date: December 14, 2012
Phase: Phase 1/Phase 2
Study type: Interventional

Primary Objective: To evaluate the long-term safety and tolerability of SAR422459 in patients with Stargardt's Macular Degeneration. Secondary Objective: To assess: - Safety - Biological activity

NCT ID: NCT01736059 Active, not recruiting - Clinical trials for Diabetic Retinopathy

Clinical Trial of Autologous Intravitreal Bone-marrow CD34+ Stem Cells for Retinopathy

Start date: July 2012
Phase: Phase 1
Study type: Interventional

This pilot study is to determine whether it would be safe and feasible to inject CD34+ stem cells from bone marrow into the eye as treatment for patients who are irreversibly blind from various retinal conditions.

NCT ID: NCT01678872 Active, not recruiting - Clinical trials for Age-Related Macular Degeneration

A Follow-up Study to Evaluate the Safety of RetinoStat® in Patients With Age-Related Macular Degeneration

Start date: August 2012
Phase: Phase 1
Study type: Interventional

The purpose of this study is to examine the long term safety of an experimental gene transfer agent, RetinoStat®, designed to treat neovascular age-related macular degeneration.

NCT ID: NCT01670162 Active, not recruiting - Clinical trials for Age Related Macular Degeneration

On-label tReatment With Intravitreal Aflibercept injectiOn for Patients With Persistent Pigment epitheliaL Detachments in Neovascular Age Related Macular Degeneration (AMD)

ROLL
Start date: August 2012
Phase: Phase 4
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of intravitreal aflibercept injection in a population of neovascular AMD patients that have been previously treated with 2.0 mg ranibizumab for persistent PEDs.

NCT ID: NCT01657669 Active, not recruiting - Clinical trials for Age Related Macular Degeneration

Short-term Clinical Effects of Intravitreal Aflibercept Injection 2.0mg as a Predictor of Long-term Results

Start date: October 2012
Phase: Phase 4
Study type: Interventional

This is an open label study to evaluate 2.0 mg intravitreal aflibercept injection administered in subject who have active choroidal neovascularization due to Age Related Macular Degeneration (AMD).